Document:

<PAGE>
                                                                   Exhibit 10.35

THIS NOTE, AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE (COLLECTIVELY, THE
"SECURITIES"), HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND
EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THE SECURITIES
ARE BEING OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SECTION 4(2)
OF THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THE SECURITIES ARE
"RESTRICTED" AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S.
PERSONS (AS SUCH TERM IS DEFINED IN REGULATION D PROMULGATED UNDER THE ACT)
UNLESS THE SECURITIES ARE REGISTERED UNDER THE ACT, PURSUANT TO REGULATION D OR
PURSUANT TO AVAILABLE EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT
AND THE COMPANY WILL BE PROVIDED WITH OPINION OF COUNSEL OR OTHER SUCH
INFORMATION AS IT MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH EXEMPTIONS ARE
AVAILABLE.

                                      NOTE

                            EMPYREAN BIOSCIENCE, INC.

                              10% CONVERTIBLE NOTE

                    DUE NOVEMBER ___, 2002 ("MATURITY DATE")

No.  ___                                                            $__________

         This Note is issued by EMPYREAN BIOSCIENCE, INC., a Delaware
corporation (the "COMPANY"), to ____________________________ (together with its
permitted successors and assigns, the "HOLDER") pursuant to an exemption from
registration under the Securities Act of 1933, as amended.

                                   ARTICLE I.

         SECTION 1.01 PRINCIPAL AND INTEREST. For value received on May ___,
2002, the Company hereby promises to pay to the order of the Holder in lawful
money of the United States of America and in immediately available funds the
principal sum of __________________(US $________), together with interest on the
unpaid principal of this Note at the rate of ten percent (10%) per year
(computed on the basis of a 365-day year and the actual days elapsed) from the
date of this Note until paid. At the Holder's option, any portion of the
unconverted principal amount and all accrued interest shall be either (a) paid
to the Holder on the Maturity Date or (b) converted in accordance with Section
1.02 herein. The amount of such unconverted principal and such accrued interest
shall be paid in (i) cash and/or (ii) shares of "Common Stock" (as defined
below), at the Holder's option.

<PAGE>

         SECTION 1.02 BONUS INTEREST. Should the Company complete a transaction
for the sale of substantially all of the assets or stock of the Company prior to
the Maturity Date, the Holder shall be entitled to bonus interest of fifty
percent (50%) of the face amount of the Note.

         SECTION 1.03 OPTIONAL CONVERSION. The Holder is entitled, at its
option, to convert at the Maturity Date, all or any part of the principal amount
of the Note, plus accrued interest, into shares (the "CONVERSION SHARES") of the
Company's common stock, $0.0001 par value ("COMMON STOCK"), at the price per
share (the "CONVERSION PRICE") equal to $0.0099. No fraction of shares or scrip
representing fractions of shares will be issued on conversion, but the number of
shares issuable shall be rounded to the nearest whole share. To convert this
Note, the Holder hereof shall deliver written notice thereof, substantially in
the form of EXHIBIT "A" to this Note, with appropriate insertions (the
"CONVERSION NOTICE"), to the Company at its address as set forth herein.

         SECTION 1.04 NO RESERVATION OF COMMON STOCK. The Holder acknowledges
that the Company does not have a sufficient number of authorized and unissued
shares of common stock to issue the Conversion Shares. A sufficient number of
the Conversion Shares shall be available and shall be reserved only upon
approval of either an increase in the Company's authorized number of shares or a
reverse stock split by the shareholders of the Company. The undersigned
acknowledges that the Company cannot guarantee that either or both of these
measures will be approved by the shareholders.

         SECTION 1.05 PIGGYBACK REGISTRATION RIGHTS. The Holder's shall have
"piggyback" registration rights for the Conversion Shares with respect to any
registration statement filed by the Company pursuant to the Securities Act of
1933, as amended.

         SECTION 1.06 INTEREST PAYMENTS. The interest so payable will be paid at
the time of maturity or conversion to the person in whose name this Note is
registered.

         SECTION 1.07 PAYING AGENT AND REGISTRAR. The Company will act as paying
agent and registrar. The Company may change any paying agent, registrar, or
Company-registrar by giving the Holder not less than ten (10) business days'
written notice of its election to do so, specifying the name, address, telephone
number and facsimile number of the paying agent or registrar. The Company may
act in any such capacity.

         SECTION 1.08 SECURITY. This Note and all payments hereon, including
principal or interest, shall be secured by all of the assets of the Company.
Liens on all of the assets of the Company currently held by Lawrence D. Bain,
Kathy Bain, Uptic Investments Corp., Richard C. Adamany, Vicky L. Adamany,
Bennett S. Rubin, Jill G. Okun and the Bennett S. Rubin Trust Under Trust
Agreement Dated November 2, 1994 Amended and Restated Under Declaration of Trust
Dated August 11, 2000 shall be subordinated to the security interest of the
Holder and the other purchasers of 10% Convertible Notes as evidenced by a
Subordination Agreement dated May ___, 2002.

                                  ARTICLE II.

         SECTION 2.01 AMENDMENTS AND WAIVER OF DEFAULT. The Note may be amended
with the prior written consent of the Holder. Without the consent of the Holder,
the Note may be

                                       2
<PAGE>

amended to cure any ambiguity, defect or inconsistency, to provide for
assumption of the Company obligations to the Holder or to make any change that
does not adversely affect the rights of the Holder.

                                  ARTICLE III.

         SECTION 3.01 EVENTS OF DEFAULT. An Event of Default is defined as
follows: (a) failure by the Company to pay the principal of, and interest on,
this Note within fifteen (15) business days of the Maturity Date of this Note;
(b) failure by the Company to advise its transfer agent to issue Common Stock to
the Holder within twenty (20) business days of the Company's receipt of the
attached Notice of Conversion from Holder; (c) failure by the Company for thirty
(30) business days after written notice from the Holder to comply in any
material respect with any of its other agreements in the Note; (d) events of
bankruptcy. The Holder may not enforce the Note except as provided herein.

                                  ARTICLE IV.

         SECTION 4.01 ANTI-DILUTION. In the event that the Company shall at any
time subdivide the outstanding shares of Common Stock, or shall issue a stock
dividend on the outstanding Common Stock, the Conversion Price shall be
proportionately decreased, and in the event that the Company shall at any time
combine the outstanding shares of Common Stock, the Conversion Price shall be
proportionately increased, effective at the close of business on the date of
such subdivision, dividend or combination as the case may be.

                                   ARTICLE V.

SECTION 5.01 NOTICE. Notices regarding this Note shall be sent to the parties at
the following addresses, unless a party notifies the other parties, in writing,
of a change of address:

If to the Company, to:    Empyrean Bioscience, Inc.
                          23800 Commerce Park Road
                          Suite A
                          Cleveland, OH 44122
                          Attention:     Richard C. Adamany
                                         President and Chief Executive Officer
                          Telephone:     (216) 360-7900
                          Facsimile:     (216) 360-7909

With a copy to:           Benesch, Friedlander, Coplan and Aronoff LLP
                          BP America Building - 200 Public Square
                          Cleveland, OH 44114
                          Attention:     Joseph G. Tegreene, Esq.
                          Telephone:     (216) 363-4643
                          Facsimile:     (216) 363-4588

If to Holder:             _________________________________________________
                          _________________________________________________
                          _________________________________________________
                          _________________________________________________

                                       3
<PAGE>

         SECTION 5.02 GOVERNING LAW. This Note shall be deemed to be made under
and shall be construed in accordance with the laws of the State of Delaware
without giving effect to the principles of conflict of laws thereof. Each of the
parties consents to the jurisdiction of the U.S. District Court sitting in the
Northern District of the State of Ohio or the state courts of the State of Ohio
sitting in Cleveland in connection with any dispute arising under this Note and
hereby waives, to the maximum extent permitted by law, any objection, including
any objection based on FORUM NON CONVENIENS to the bringing of any such
proceeding in such jurisdictions.

         SECTION 5.03 SEVERABILITY. The invalidity of any of the provisions of
this Note shall not invalidate or otherwise affect any of the other provisions
of this Note, which shall remain in full force and effect.

         SECTION 5.04 ENTIRE AGREEMENT AND AMENDMENTS. This Note represents the
entire agreement between the parties hereto with respect to the subject matter
hereof and there are no representations, warranties or commitments, except as
set forth herein. This Note may be amended only by an instrument in writing
executed by the parties hereto.

         SECTION 5.05 COUNTERPARTS. This Note may be executed in multiple
counterparts, each of which shall be an original, but all of which shall be
deemed to constitute on instrument.

         IN WITNESS WHEREOF, with the intent to be legally bound hereby, the
Company as executed this Note as of the date first written above.

                                    EMPYREAN BIOSCIENCE, INC.

                                    By: /s/ Richard C. Adamany
                                        ----------------------------------------
                                    Name:    Richard C. Adamany
                                    Title:   President & Chief Executive Officer

                                       4
<PAGE>

                                   EXHIBIT "A"

                              NOTICE OF CONVERSION

           (TO BE EXECUTED BY THE HOLDER IN ORDER TO CONVERT THE NOTE)

TO:

         The undersigned hereby irrevocably elects to convert $_________________
of the principal amount of the attached Note into Shares of Common Stock of
Empyrean Bioscience, Inc., according to the conditions stated therein, as of the
Conversion Date written below.

CONVERSION DATE:                          November ____ , 2002

APPLICABLE CONVERSION PRICE:  _______________________________________________

SIGNATURE:                    _______________________________________________

NAME:                         _______________________________________________

ADDRESS:                      _______________________________________________

                                      A-1<PAGE>
                                                                   Exhibit 10.36

VOID AFTER 5:00 P.M., NEW YORK TIME ON MAY _____, 2005
WARRANT TO PURCHASE _____________ SHARES OF COMMON STOCK

  ----------------------------------------------------------------------------
                        WARRANT TO PURCHASE COMMON STOCK

                                       OF

                            EMPYREAN BIOSCIENCE, INC.

 ------------------------------------------------------------------------------

                   THIS WARRANT AND THE SHARES OF COMMON STOCK
                     ISSUABLE PURSUANT TO THIS WARRANT HAVE
              NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
                  AS AMENDED (THE "ACT"), AND MAY NOT BE SOLD,
                     PLEDGED OR OTHERWISE TRANSFERRED UNLESS
                  REGISTERED UNDER THE ACT OR AN EXEMPTION FROM
                         SUCH REGISTRATION IS AVAILABLE.

         FOR VALUE RECEIVED, Empyrean Bioscience, Inc., a Delaware corporation
(the "Company"), grants the following rights to _______________________________
("Holder'):

                                   ARTICLE I.

                                  DEFINITIONS.

         As used herein, the following terms shall have the following meanings,
unless the context shall otherwise require:

            (a) "Common Stock" shall mean the common stock, par value $0.0001,
of the Company.

            (b) "Corporate Office" shall mean the office of the Company (or its
successor) at which at any particular time its principal business shall be
administered.

            (c) "Exercise Date" shall mean any date upon which the Holder shall
give the Company a Notice of Exercise.

                                       1
<PAGE>

            (d) "Exercise Price" shall mean the price to be paid to the Company
for each share of Common Stock to be purchased upon exercise of this Warrant in
accordance with the terms hereof which shall be $0.0099. (e) "Expiration Date"
shall mean 5:00 p.m. (New York time) on May ____, 2005.

            (f) "Subscription Agreement" shall mean that certain Subscription
Agreement dated May ____, 2002 pursuant to which this Warrant has been issued.

            (g) "SEC" shall mean the United States Securities and Exchange
Commission.

            (h) "Transfer Agent" shall mean the Company's transfer agent or its
authorized successor.

            (i) "Underlying Shares" shall mean the shares of Common Stock
issuable upon exercise of the Warrant.

                                   ARTICLE 2.

                             EXERCISE AND AGREEMENTS

         2.1 EXERCISE OF WARRANT. This Warrant shall entitle Holder to purchase
up to __________ shares of Common Stock (the "Shares") at the Exercise Price.
This Warrant shall be exercisable at any time and from time to time on or after
November ____, 2002 and prior to the Expiration Date (the "Exercise Period").
This Warrant and the right to purchase shares of Common Stock hereunder shall
expire and become void at the Expiration Date.

         2.2      MANNER OF EXERCISE.

                  (a) Holder may exercise this Warrant at any time and from time
to time during the Exercise Period, in whole or in part (but not in
denominations of fewer than 10,000 shares, except upon an exercise of this
Warrant with respect to the remaining balance of shares purchasable hereunder at
the time of exercise), by delivering to the Company (i) a duly executed Notice
of Exercise in substantially the form attached as Appendix 1 hereto and (ii) a
bank cashiers, certified check, or wire transfer for the aggregate Exercise
Price of the shares being purchased.

                  (b) From time to time upon exercise of this Warrant, in whole
or part, in accordance with its terms, the Company will deliver stock
certificates to the Holder representing the number of shares of Common Stock
being purchased pursuant to such exercise, subject to adjustment as described
herein.

                                       2
<PAGE>

                  (c) Promptly following any exercise of this Warrant, if the
Warrant has not been fully exercised and has not expired, the Company will
deliver to the Holder a new Warrant for the balance of the shares of Common
Stock covered hereby.

         2.3 TERMINATION. All rights of the Holder in this Warrant, to the
extent they have not been exercised, shall terminate on the Expiration Date.

         2.4 NO RIGHTS PRIOR TO EXERCISE. Prior to its exercise pursuant to
Section 2.2 above, this Warrant shall not entitle the Holder to any voting or
other rights as a holder of shares of Common Stock.

         2.5 ADJUSTMENTS. In case of any reclassification, capital
reorganization, stock dividend or other change of outstanding shares of Common
Stock, or in case of any consolidation or merger of the Company with or into
another corporation (other than a consolidation or merger in which the Company
is the continuing corporation and which does not result in any reclassification,
capital reorganization, stock dividend or other change of outstanding shares or
Common Stock) or in case of any sale or conveyance to another corporation of the
property of the Company as, or substantially as, an entirety (other than a
sale/leaseback, mortgage or other financing transaction), the Company shall
cause effective provision to be made so that the Holder shall have the right
thereafter, by exercising this Warrant, to purchase the kind and number of
shares of stock or other securities or property (including cash) receivable upon
such reclassification, capital reorganization, stock dividend or other change,
consolidation, merger, sale or conveyance as the Holder would have been entitled
to receive had the Holder exercised this Warrant in full immediately before such
reclassification, capital reorganization, stock dividend or other change,
consolidation, merger, sale or conveyance. Any such provision shall include
provision for adjustments that shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Section 2.5. The foregoing
provisions shall similarly apply to successive reclassifications, capital
reorganizations, stock dividends and other changes of outstanding shares of
Common Stock and to successive consolidations, mergers, sales or conveyances.

         2.6 FRACTIONAL SHARES. No fractional shares of Common Stock shall be
issuable upon exercise or conversion of this Warrant and the number of shares to
be issued shall be rounded down to the nearest whole share. If a fractional
share interest arises upon any exercise or conversion of the Warrant, the
Company shall eliminate such fractional share interest by paying Holder the
amount computed by multiplying the fractional interest by the closing bid price
of a full share of Common Stock on the date of the Notice of Exercise.

                                       3
<PAGE>

                                   ARTICLE 3.

                  REPRESENTATIONS AND COVENANTS OF THE COMPANY.

         3.1 REPRESENTATIONS AND WARRANTIES. The Company hereby represents and
warrants to the Holder as follows:

                  (a) The Company does not currently have available a sufficient
number of shares of common stock for issuance or exercise of the Warrants.
Following shareholder approval of an increase in the Company's authorized
shares, all shares of Common Stock which will be issued upon the exercise of the
purchase right represented by this Warrant will, upon issuance, be duly
authorized, validly issued, fully-paid and nonassessable, and free of any liens
and encumbrances except for restrictions on transfer provided for herein or
under applicable federal and state securities laws, and not subject to any
pre-emptive rights.

                  (b) The Company is a corporation duly organized and validly
existing under the laws of the State of Delaware, and has the full power and
authority to issue this Warrant and to comply with the terms hereof. The
execution, delivery and performance by the Company of its obligations under this
Warrant, including, without limitation, the issuance of the shares of Common
Stock upon any exercise of the Warrant have been duly authorized by all
necessary corporate action. This Warrant has been duly executed and delivered by
the Company and is a valid and binding obligation of the Company, enforceable in
accordance with its terms, except as enforcement may be limited by applicable
bankruptcy, insolvency, reorganization or similar laws affecting enforceability
of creditors' rights generally and except as the availability of the remedy of
specific enforcement, injunctive relief or other equitable relief is subject to
the discretion of the court before which any proceeding therefore may be
brought.

                  (c) The Company is not subject to or bound by any provision of
any certificate or articles of incorporation or by-laws, mortgage, deed of
trust, lease, note, bond, indenture, other instrument or agreement, license,
permit, trust, custodianship, other restriction or any applicable provision of
any law, statute, rule, regulation, judgment, order, writ, injunction or decree
of any court, governmental body, administrative agency or arbitrator which could
prevent or be violated by or under which there would be a default (or right of
termination) as a result of the execution, delivery and performance by the
Company of this Warrant.

                                   ARTICLE 4.

                           SECURITIES LAW COMPLIANCE.

         The shares of Common Stock issuable on exercise of this Warrant will be
acquired for Holder's own account for investment and not with a view to, or for
resale in connection with, any distribution of the shares within the meaning of
the Securities Act of 1933. Holder acknowledges that it is aware that the shares
of Common Stock issuable upon exercise of this Warrant have not been registered
pursuant to the Securities Act of 1933 (the "Act"), nor is it

                                       4
<PAGE>

intended that they be registered and the Holder has no right to require that
they be registered, under the Act or under any state securities laws. The Holder
agrees that the shares of Common Stock may not be sold in the absence of
registration unless such sale is exempt from registration under the Act and any
applicable state securities laws. The Holder also acknowledges that he shall be
responsible for compliance with all conditions on transfer imposed by any
Commissioner of Securities of any state and for any expenses incurred by the
Company for legal or accounting services in connection with reviewing such
proposed transfer or issuing opinions in connection therewith. The certificate
for the shares of Common Stock issuable on exercise of this Warrant shall bear
the following restrictive legend:

         THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
         UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OF THE UNTIED STATES OF
         AMERICA (THE "ACT") OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED
         STATES ("STATE ACT"). THESE SECURITIES HAVE BEEN ACQUIRED FOR
         INVESTMENT AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED, OR
         OTHERWISE TRANSFERRED FOR VALUE, DIRECTLY OR INDIRECTLY, IN THE ABSENCE
         OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE ACT
         AND COMPLIANCE WITH APPLICABLE STATE ACTS, OR PURSUANT TO AN EXEMPTION
         FROM REGISTRATION UNDER THE ACT AND UNDER APPLICABLE STATE ACTS, THE
         AVAILABILITY OF WHICH IS ESTABLISHED TO THE SATISFACTION OF THE
         COMPANY.

         If (but without any obligation to do so under this Agreement) the
Company proposes to register (including for this purpose a registration effected
by the Company for shareholders other than the Holder) any of its stock or other
securities under the Act in connection with the public offering of such
securities solely for cash (other than a registration relating solely to the
sale of securities to participants in a Company stock plan, or a registration on
any form which does not include substantially the same information as would be
required to be included in a registration statement covering the issuance of the
Underlying Shares, or a registration of an offering of securities, the
underwriter of which objects to registration of additional securities), the
Company shall, at such time, promptly give to Holder written notice of such
registration. Upon the written request of the Holder given within twenty days
after mailing of such notice by the Company, the Company shall cause to be
registered under such registration statement such Underlying Shares as the
Holder has requested to be registered.

                                   ARTICLE 5.

                                 MISCELLANEOUS.

         5.1 TRANSFER. This Warrant may not be transferred or assigned, in whole
or in part, at any time, except in compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without
limitation, the delivery of an investment representation letter and a legal
opinion reasonably satisfactory to the Company), provided that

                                       5
<PAGE>

this Warrant may not be transferred or assigned such that either the Holder or
any transferee will, following such transfer or assignment, hold a Warrant for
the right to purchase fewer than 5,000 shares of Common Stock.

         5.2 TRANSFER PROCEDURE. Subject to the provisions of Section 5.1,
Holder may transfer or assign this Warrant by giving the Company notice setting
forth the name, address and taxpayer identification number of the transferee or
assignee, if applicable (the "Transferee") and surrendering this Warrant to the
Company for reissuance to the Transferee (and the Holder, in the event of a
transfer or assignment of this Warrant in part). (Each of the persons or
entities in whose name any such new Warrant shall be issued is herein referred
to as a Holder").

         5.3 LOSS, THEFT, DESTRUCTION OR MUTILATION. If this Warrant shall
become mutilated or defaced or be destroyed, lost or stolen, the Company shall
execute and deliver a new Warrant in exchange for and upon surrender and
cancellation of such mutilated or defaced Warrant or, in lieu of and in
substitution for such Warrant so destroyed, lost or stolen, upon the Holder
filing with the Company evidence to it that such Warrant has been so mutilated,
defaced, destroyed, lost or stolen. However, the Company shall be entitled, as a
condition to the execution and delivery of such new Warrant, to demand indemnity
satisfactory to it and payment of the expenses and charges incurred in
connection with the delivery of such new Warrant. Any Warrant so surrendered to
the Company shall be canceled.

         5.4 NOTICES. All notices and other communications from the Company to
the Holder or vice versa shall be deemed delivered and effective when given
personally, by facsimile transmission and confirmed in writing or mailed by
first-class registered or certified mail, postage prepaid at such address and/or
facsimile number as may have been furnished to the Company or the Holder, as the
case may be, in writing by the Company or the Holder from time to time.

         5.5 WAIVER. This Warrant and any term hereof may be changed, waived, or
terminated only by an instrument in writing signed by the party against which or
whom enforcement of such change, waiver, discharge or termination is sought.

         5.6 GOVERNING LAW. This Warrant shall be governed by and construed in
accordance with the laws of the State of Delaware, without giving effect to its
principles regarding conflicts of law.

Dated: _______________________          Empyrean Bioscience, Inc.

Attest: ___________________             By:/s/ Richard C. Adamany
                                           -------------------------------------
                                           Richard C. Adamany, President & Chief
                                              Executive Officer

                                       6
<PAGE>

                               NOTICE OF EXERCISE

         TO:      EMPYREAN BIOSCIENCE, INC.

         (1) The undersigned hereby elects to purchase ________ shares of the
Common Stock of Empyrean Bioscience, Inc., a Delaware corporation, pursuant to
the provisions of Article 2 of the attached Warrant, and tenders herewith
payment of the purchase price for such shares in full.

(2) In exercising this Warrant, the undersigned hereby confirms and acknowledges
that the shares of Common Stock to be issued upon this exercise are being
acquired solely for the account of the undersigned and not as a nominee for any
other party, and for investment, and that the undersigned will not offer, sell
or otherwise dispose of any such shares of Common Stock except under
circumstances that will not result in a violation of the Securities Act of 1933,
as amended, or any applicable state securities laws.

(3) Please issue a certificate or certificates representing said shares of
Common Stock in the name of the undersigned or in such other name as is
specified below:

Date:__________________                   __________________________________
                                                        (Name)

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]